People who stop taking GLP-1 medications—such as Ozempic, Wegovy, and other similar weight-loss drugs—are likely to regain the weight they lost within about 18 months, according to a comprehensive study. This research, which reviewed 37 prior studies involving around 9,000 participants, found that former users of these medications regain weight up to four times faster than those who lose weight through behavioral methods like diet and exercise.
GLP-1 medications work by suppressing appetite, slowing digestion, and prolonging feelings of fullness. Originally developed to treat Type 2 diabetes, drugs like semaglutide (the active ingredient in Ozempic and Wegovy) have become popular for weight management amid the global obesity epidemic, which affects nearly two billion adults and increases the risk of serious health complications.
Published in the British Medical Journal, the study highlights that while weight loss through these drugs improves cardiovascular and metabolic health markers, these benefits decline rapidly once treatment ends. The authors noted that weight tends to return at a rate of approximately 0.8 kg per month after discontinuation, with a projected return to baseline weight within 1.5 years.
READ MORE: Young Motorcyclist Dies in Cotswolds Crash; Driver Arrested
READ MORE: Paedophile Caught with Disturbing Evidence at Gloucester Station
Given obesity’s chronic and relapsing nature, the findings suggest that ongoing treatment with weight management medications may be necessary to sustain health benefits. The study cautions against using these medications short-term without comprehensive lifestyle support and stresses the importance of continued research into effective long-term weight management strategies.
An additional study from the University of Cambridge reinforces these conclusions, revealing that patients regained 60% of their original weight loss within one year after stopping the medication. Researchers explained that while these drugs act like “brakes” on appetite—helping people eat less—removing that effect often results in rapid weight rebound. However, some individuals retain healthier eating habits formed during treatment, which may help them avoid returning fully to their original weight.
Medical experts emphasize that patients discontinuing GLP-1 medications should receive guidance on diet and exercise to minimize weight regain. Novo Nordisk, the manufacturer of Ozempic and Wegovy, acknowledged the chronic nature of obesity and affirmed that ongoing treatment is essential to maintain weight loss and health improvements, much like managing other long-term conditions such as diabetes or hypertension.